Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session

Evolution of a Fully Automated Acoustic Ejection Mass Spectrometry (AEMS) Platform for Lead Discovery and Optimization

About This Webinar

Sponsored by HighRes® Biosolutions

When designing automation platforms in the early drug discovery space, there is a balance present between scoping for current needs and being ready for non-certain future directions. Instrument technologies evolve rapidly, and incorporating new workflows onto existing automation is a critical option to minimize implementation time and capital budget.

With the deployment of acoustic ejection mass spectrometry (AEMS, or Echo® MS) technology at BMS, our strategy was clear that to maximize investment in and impact of the instrumentation, a high-throughput detection model would require integration on automation. With significant automation footprint in place after several site evolutions, an existing platform was upgraded to enable 24/7 processing. With this proven success, a second Echo® MS unit was integrated, doubling capacity to generate data from upstream HTS automation platforms performing the assays.

Above topics will be covered, along with continuing efforts to improve performance in areas such as error capture and data movement. This automated Echo® MS platform has been successfully deployed for label-free analysis of many critical early drug discovery assays such as activity-based screens, mechanistic studies, HTS, and HT-ADME. Examples demonstrating the excellent speed, data quality and robustness of the platform will be presented in the webinar.

Learning Objectives:
o Designing automation that is future-flexible
o Integrating novel instrumentation onto automation
o Managing instrument integration lifecycle (driver development, error capture, data movement)
o Leveraging high-throughput mass spectrometry (HTMS) for label-free screening
o Research collaboration on novel technologies

Privacy Policy

Who can view:
Webinar Price: Free
Webinar ID: 4af1ce2e1781
Featured Presenters
Webinar hosting presenter
Scientific Director Bristol Myers Squibb
Chase has 20+ years as an automation engineer/scientist in the field of early drug discovery executing lead discovery (uHTS), lead evaluation (SAR/SLR), lead profiling (ADME-Tox) and compound management operations. Currently a Scientific Director at Bristol Myers Squibb, Head of Core Automation, responsible for screening automation within Leads Discovery and Optimization (LDO) department across Princeton, San Francisco, and Cambridge (MA) locations. Schreyer Honors College Graduate of the Pennsylvania State University with a B.S. in Chemical Engineering.
Webinar hosting presenter
Director, Bristol Myers Squibb
Wilson has 20+ years of experience in high-throughput bioanalytical mass spectrometry in various areas of drug discovery and development. He is currently a Scientific Director in the Leads Discovery and Optimization (LDO) department at Bristol Myers Squibb in Princeton, NJ, where he oversees a team providing in vitro ADME profiling and high-throughput mass spectrometry support for hit generation, hit to lead, and lead optimization efforts. Wilson received his B.S. in Chemistry from Fudan University, and his Ph.D. in Analytical Chemistry from Georgia Institute of Technology.
Attended (117)